M
Marie-Jeanne T. F. D. Vrancken Peeters
Researcher at Netherlands Cancer Institute
Publications - 104
Citations - 3294
Marie-Jeanne T. F. D. Vrancken Peeters is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 26, co-authored 73 publications receiving 2564 citations.
Papers
More filters
Journal ArticleDOI
Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.
M. Donker,Marieke E. Straver,Jelle Wesseling,Claudette E. Loo,Margaret Schot,C.A. Drukker,Harm van Tinteren,Gabe S. Sonke,Emiel J. Th. Rutgers,Marie-Jeanne T. F. D. Vrancken Peeters +9 more
TL;DR: This study shows that marking and selectively removing metastatic lymph nodes after neoadjuvant systemic treatment has a high identification rate and a low false negative rate and the tumor response in the marked lymph node may be used to tailor further axillary treatment after NST.
Journal ArticleDOI
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
Marieke E. Straver,Annuska M. Glas,Juliane Hannemann,Jelle Wesseling,Marc J. van de Vijver,Emiel J. Th. Rutgers,Marie-Jeanne T. F. D. Vrancken Peeters,Harm van Tinteren,Laura J. van't Veer,Sjoerd Rodenhuis +9 more
TL;DR: The 70-gene signature (MammaPrint™) is a prognostic tool used to guide adjuvant treatment decisions and its value to predict chemosensitivity in the neoadjuvant setting was assessed.
Journal ArticleDOI
Magnetic Resonance Imaging Response Monitoring of Breast Cancer During Neoadjuvant Chemotherapy: Relevance of Breast Cancer Subtype
Claudette E. Loo,Marieke E. Straver,Sjoerd Rodenhuis,Sara H. Muller,Jelle Wesseling,Marie-Jeanne T. F. D. Vrancken Peeters,Kenneth G. A. Gilhuijs +6 more
TL;DR: MRI during NAC to monitor response is effective in triple-negative or HER2-positive disease but is inaccurate in ER-positive/HER2-negative breast cancer.
Journal ArticleDOI
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial
Mette S. van Ramshorst,Anna van der Voort,Erik van Werkhoven,I.A.M. Mandjes,Inge Kemper,Vincent O. Dezentjé,Irma M. Oving,Aafke H. Honkoop,Lidwine W. Tick,Agnes J. van de Wouw,Caroline M.P.W. Mandigers,Laurence J. C. van Warmerdam,Jelle Wesseling,Marie-Jeanne T. F. D. Vrancken Peeters,Sabine C. Linn,Sabine C. Linn,Gabe S. Sonke +16 more
TL;DR: This open-label, randomised, controlled, phase 3 trial investigated whether the addition of anthracyclines would improve pathological complete response compared with a carboplatin-taxane regimen, when given in combination with the HER2-targeted agents trastuzumAB and pertuzumab.
Journal ArticleDOI
Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response
Jorma J. de Ronde,Juliane Hannemann,Hans Halfwerk,Lennart Mulder,Marieke E. Straver,Marie-Jeanne T. F. D. Vrancken Peeters,Jelle Wesseling,Marc J. van de Vijver,Lodewyk F. A. Wessels,Sjoerd Rodenhuis +9 more
TL;DR: Molecular subtyping suggests the existence of a HER2+IHC/LuminalmRNA group that responds poorly to trastuzumab-based chemotherapy, and further subdivision into molecular subgroups does not offer a clear advantage in treatment selection.